Abzena
About Abzena
Abzena is a Healthcare company based in Cambridge (United Kingdom) founded in 2001, and was acquired by Welsh, Carson, Anderson & Stowe in August 2018. Provider of antibody discovery, cell line development, and bio analytics services. Abzena has raised $67.11 million across 11 funding rounds from investors including Mercia, Welsh, Carson, Anderson & Stowe and YFM Equity Partners. The company has 306 employees. Abzena has completed 1 acquisition, including PacificGMP. Its chief executive, as recorded, is Jonathan Goldman. Its website abzena.com draws about 15 thousand monthly visits. Abzena offers products and services including Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development. Its focus areas include Biopharma Outsourcing, CDMO and Diversified. Its legal entity is ABZENA LIMITED.
Company details
Abzena was founded in 2001 and is headquartered in Cambridge, United Kingdom. Operations focus on the biotechnology sector, where services in antibody discovery, cell line development, and bio analytics are delivered. Additional offerings include proprietary technologies, mammalian and bio conjugates manufacturing, peptide synthesis, analytical development, and bio assays to support pharmaceutical and research needs.
- Headquarters Cambridge, United Kingdom
- Employees 306
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abzena.com
- Social LinkedIn X
- Acquired by Welsh, Carson, Anderson & Stowe (Aug 2018)
- Legal Name Abzena Limited
- Date of Incorporation 25 Mar, 2014
- Jurisdiction CAMBRIDGE
- Annual Revenue$22.12 M (USD)119as on Dec 31, 2016
- Net Profit-$41.47 M (USD)as on Dec 31, 2019
- Total Equity Funding$67.11M (USD)
in 11 rounds
- Latest Funding Round$65M (USD), Post-IPO
Mar 2022
- InvestorsMercia
& 8 more
- Employee Count306
- Investments & Acquisitions
- Acquired byWelsh, Carson, Anderson & Stowe
(Aug 2018)
Products & Services of Abzena
Abzena offers a comprehensive portfolio of products and services, including Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development.
Service for identifying high-affinity antibodies with desired activity.
Development of ADCs and related conjugates for targeted therapies.
Generation of cell lines for biologics production and GMP processes.
Optimization of formulations for monoclonal antibodies and conjugates.
Funding Insights of Abzena
Abzena has successfully raised a total of $67.11M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.11M
- Total Rounds 11
- Last Round Post-IPO — $65M
- First Round $4.57M
(Jun 2007)
- Investors Count 9
Latest 10 of 11 funding rounds of Abzena with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $65M | Post-IPO | – | – | |
| Jul 2020 | $10M | Post-IPO | – | – | |
| Apr 2017 | $3.71M | Post-IPO | – | – | |
| Apr 2017 | $31.14M | Post-IPO | – | – | – |
| Nov 2015 | $30.31M | Post-IPO | – | – | – |
| Jul 2014 | $34.27M | Series C | – | – | – |
| Jul 2013 | $20.1M | Series B | – | Imperial Innovations, Invesco Perpetual | – |
| Sep 2011 | $3.45M | Series A | – | Imperial Innovations | |
| Feb 2010 | $4.71M | Series A | – | Imperial Innovations | |
| Nov 2007 | $724,573 | Grant | – | – | – |
9 investors in total: 9 institutional.
Investors in Abzena
Abzena has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Welsh, Carson, Anderson & Stowe and YFM Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare and technology sectors are targeted for private equity investments. | 1979 | wcas.com | New York, United States | |
Biospring is engaged in partnering with pharma services businesses. | biospring.com | New York, United States | ||
Investments in startups are focused on Europe and the US. | 1986 | imperialinnovations.co.uk | London, United Kingdom | |
Private equity firm focused on multiple sectors | 1982 | yfmep.com | Leeds, United Kingdom | |
| longbow.co.uk | ||||
Creates, builds and invests in pioneering technology companies spun-out from Univs Cambridge, Oxford, and UCL | 1986 | touchstoneinnovations.com | London, United Kingdom | |
Diversified investment management services are provided globally. | 1973 | invescoperpetual.co.uk | ||
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | ||
Tax-efficient investment opportunities are provided by ProVen for retail investors. | provenvcts.co.uk | London, United Kingdom |
Investor details for Abzena
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abzena
44 people are tracked at Abzena (24 in leadership, 20 in team); the tracked headcount is 306.
| Name | Role | Group |
|---|---|---|
Jonathan Goldman | CEO | Leadership |
Brett Verstak | Director - Cell Line Development | Leadership |
🧬 Greg Downs | Vice President Of Business Development | Leadership |
Austin McKinsey | Associate Director PD Bioconjugation | Leadership |
Stephen Verespy | Senior Director, Scientific Operations | Leadership |
Gavin Murdoch | Senior VP BD And Commercial Strategy | Leadership |
Erika Kovacs | Senior Director, Bioassays | Leadership |
Geoffrey Glass | Chief Executive Officer | Leadership |
Campbell Bunce | Chief Scientific Officer | Leadership |
Joseph E. Letizia | Vice President Of Business Development | Leadership |
Sudha Krishnan | Vice President Of Business Development | Leadership |
Kimberly Burrell | Senior Vice President Of Global Marketing | Leadership |
Patrick Haddad | Vice President, Business Development | Leadership |
Richard Mochor | Director Of Digital Marketing | Leadership |
Kevin Ranke | Senior Director Of Business Development | Leadership |
Johanna Midelet | Director Bioconjugation And Chemistry | Leadership |
Rob Holgate | VP Research & Innovation | Leadership |
Nicolas Camper | Vice President - Adcs & Bioconjugates | Leadership |
Rebecca Goydel | Scientific Director - Business Development | Leadership |
Daniel Giroux | Vice President, Development | Leadership |
24 more people are available in the full profile.
Complete people profiles for Abzena
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abzena
Abzena has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PacificGMP.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Contract manufacturing in cGMP and non-GMP biologics is provided. | pacificgmp.com | San Diego, United States | 2005 | Sep 2015 | $7.7M |
Complete acquisition details for Abzena
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abzena
6 dated milestones of Abzena across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Abzena is founded.
- Funding First funding round of $4.6M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires PacificGMP.
- Exit Acquired by Welsh, Carson, Anderson & Stowe.
- Funding Latest funding round, Post-IPO, of $65.0M.
Web traffic of Abzena
The website of Abzena (abzena.com) receives about 14.8K visits a month.
- Monthly visits14.8K
▼ 5.2% vs previous month
Websites whose visitors overlap most with Abzena. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stemedica.com | 100% | View details | |||
| abdesignlabs.com | 92% | 4.7K | #4,128,811 | View details | |
| carterra-bio.com | 92% | 6.4K | #3,116,321 | View details | |
precisionantibody.com | precisionantibody.com | 92% | #3,295,457 | – | |
| azenta.com | 81% | 142.4K | #244,494 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Abzena
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abzena
Complete news archive for Abzena
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abzena
Abzena was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Abzena is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Jonathan Goldman is the CEO of Abzena, as recorded in our data.
Abzena is a funded company, having raised a total of $67.11M across 11 funding rounds to date. The company's 1st funding round was a Grant of $724.57K, raised on Jun 2007.
Abzena has 306 employees.
Annual revenue of Abzena is $22.12M as on Dec 31, 2016.
Abzena was founded in 2001 and is headquartered in Cambridge, United Kingdom. Operations focus on the biotechnology sector, where services in antibody discovery, cell line development, and bio analytics are delivered. Additional offerings include proprietary technologies, mammalian and bio conjugates manufacturing, peptide synthesis, analytical development, and bio assays to support pharmaceutical and research needs.
Abzena offers Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development.
Abzena has made 1 acquisition, including PacificGMP.
Abzena has 9 investors. Key investors include Mercia, Welsh, Carson, Anderson & Stowe, YFM Equity Partners, Invesco Perpetual, and Imperial Innovations.
Abzena operates through Abzena Limited.
Yes. Abzena was acquired by Welsh, Carson, Anderson & Stowe in August 2018.